Literature DB >> 20520592

A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.

Maoyin Pang1, Li Ma, Rujun Gong, Evelyn Tolbert, Haiping Mao, Murugavel Ponnusamy, Y Eugene Chin, Haidong Yan, Lance D Dworkin, Shougang Zhuang.   

Abstract

Accumulation of both interstitial myofibroblasts and excessive production of extracellular matrix proteins is a common pathway contributing to chronic kidney disease. In a number of tissues, activation of STAT3 (signal transducer and activator of transcription 3) increases expression of multiple profibrotic genes. Here, we examined the effect of a STAT3 inhibitor, S3I-201, on activation of renal interstitial fibroblasts and progression of renal fibrosis. Treatment of cultured rat renal interstitial fibroblasts with S3I-201 inhibited their activation, as evidenced by dose- and time-dependent blockade of alpha-smooth muscle actin and fibronectin expression. In a mouse model of renal interstitial fibrosis induced by unilateral ureteral obstruction, STAT3 was activated, and administration of S3I-201 attenuated both this activation and extracellular matrix protein deposition following injury. S3I-201 reduced infiltration of the injured kidney by inflammatory cells and suppressed the injury-induced expression of fibronectin, alpha-smooth muscle actin, and collagen type-1 proteins, as well as the expression of multiple cytokines. Furthermore, S3I-201 inhibited proliferation and induced apoptosis preferentially in renal interstitial fibroblasts of the obstructed kidney. Thus, our results suggest that increased STAT3 activity mediates activation of renal interstitial fibroblasts and the progression of renal fibrosis. Inhibition of STAT3 signaling with S3I-201 may hold therapeutic potential for fibrotic kidney diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20520592     DOI: 10.1038/ki.2010.154

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  116 in total

Review 1.  Necroinflammation in Kidney Disease.

Authors:  Shrikant R Mulay; Andreas Linkermann; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2015-09-02       Impact factor: 10.121

Review 2.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

3.  Pentraxin 3 inhibits acute renal injury-induced interstitial fibrosis through suppression of IL-6/Stat3 pathway.

Authors:  Yuefei Xiao; Nainin Yang; Qingxian Zhang; Yiping Wang; Songtao Yang; Zhanxiao Liu
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

4.  The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling.

Authors:  Petros Andrikopoulos; Julius Kieswich; Sabrina Pacheco; Luxme Nadarajah; Steven Michael Harwood; Caroline E O'Riordan; Christoph Thiemermann; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2018-12-10       Impact factor: 10.121

5.  The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.

Authors:  N Prevete; F Liotti; C Visciano; G Marone; R M Melillo; A de Paulis
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Fluorofenidone protects against renal fibrosis by inhibiting STAT3 tyrosine phosphorylation.

Authors:  Juan Tang; Chun-yan Liu; Miao-miao Lu; Jing Zhang; Wen-juan Mei; Wen-jun Yang; Yan-yun Xie; Ling Huang; Zhang-zhe Peng; Qiong-jing Yuan; Ji-shi Liu; Gao-yun Hu; Li-jian Tao
Journal:  Mol Cell Biochem       Date:  2015-06-02       Impact factor: 3.396

Review 7.  Renal interstitial fibrosis: mechanisms and evaluation.

Authors:  Alton B Farris; Robert B Colvin
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

8.  Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis.

Authors:  Na Liu; Jian-Kan Guo; Maoyin Pang; Evelyn Tolbert; Murugavel Ponnusamy; Rujun Gong; George Bayliss; Lance D Dworkin; Haidong Yan; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

Review 9.  Histone deacetylases as targets for treatment of multiple diseases.

Authors:  Jinhua Tang; Haidong Yan; Shougang Zhuang
Journal:  Clin Sci (Lond)       Date:  2013-06       Impact factor: 6.124

10.  Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis.

Authors:  Yunhe Zhang; Jianan Zou; Evelyn Tolbert; Ting C Zhao; George Bayliss; Shougang Zhuang
Journal:  FASEB J       Date:  2020-04-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.